Otsuka Pakistan Limited

OTSU

PK0038001019

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
129.4 ^PKR	+0.99%		-1.72%	-7.45%

02-29	Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
02-28	Otsuka Pakistan Limited Announces Board Changes	CI

Otsuka Pakistan Limited Announces Board Appointments

November 02, 2021 at 05:46 pm

Otsuka Pakistan Limited informed Pakistan Stock Exchange that Mr. Muhammad Taufiq Feroz and Mr. Sajid Ali have been appointed as Directors of the Board of the Company with effect from November 01, 2021.

Latest news about Otsuka Pakistan Limited

Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-29	CI
Otsuka Pakistan Limited Announces Board Changes	02-27	CI
Otsuka Pakistan Limited Announces Chief Executive Officer Changes	02-26	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	31/10/23	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23	CI
Otsuka Pakistan Limited Approves Executive Changes	25/08/23	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	28/04/23	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	01/03/23	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	31/10/22	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2022	09/09/22	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2022	08/09/22	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	28/04/22	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	04/03/22	CI
Otsuka Pakistan Limited Announces Board Appointments	02/11/21	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2021	27/10/21	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2021	31/08/21	CI
Otsuka Pakistan Limited Announces Final Cash Dividend for the Year Ended June 30, 2021	31/08/21	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021	27/04/21	CI
Otsuka Pakistan Limited Announces Appointment of Chief Executive Officer of Otsuka Pakistan Limited	03/03/21	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020	25/02/21	CI
Otsuka Pakistan Limited Reports Earnings Results for the First Quarter Ended September 30, 2020	22/10/20	CI
Otsuka Pakistan Limited Reports Earnings Results for the Full Year Ended June 30, 2020	01/09/20	CI
Shanghai MicroPort Medical Co., Ltd. Enters into the Agreement with Otsuka Pakistan Limited	26/04/20	CI
Otsuka Pakistan Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020	22/04/20	CI
Otsuka Pakistan Limited Reports Earnings Results for the Second Quarter Ended December 31, 2019	25/02/20	CI

Chart Otsuka Pakistan Limited

Duration

Period

More charts

Company Profile

Otsuka Pakistan Limited is a Pakistan-based company engaged in the manufacturing, marketing and distribution of intravenous (IV) infusions and trading in pharmaceutical products, nutritional foods, and medical equipment. It is primarily focused on IV solutions and has a range of electrolyte solutions, carbohydrate solutions, and clinical nutrition products. Its products include intravenous solutions, medical devices, clinical nutrition, therapeutic drugs and nutraceutical products. Its intravenous solutions include electrolyte solutions, standard solutions, ampoules, OTSUZOL, OTSUMOL infusion, and others. Its medical devices include urea breath test (UBT), Plasline solution, EUCATECH and Support C. Its clinical nutrition products include Aminoleban Oral, AMINOVEL 600, PAN-AMIN G, and AMINOLEBAN INJECTION. Its therapeutic drugs include Pletaal and Mucosta. Its nutraceutical products include ORTie, which is a special combination of dry salts and vitamin C to be mixed with safe water.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
OTSUKA PAKISTAN LIMITED	-7.45%	5.63M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B